Research Topics
| Felix A RatjenSummaryAffiliation: The Hospital for Sick Children Country: Canada Publications
| Collaborators
|
Detail Information
Publications
New therapies in cystic fibrosisFelix Ratjen
Division of Respiratory Medicine, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada
Curr Pharm Des 18:614-27. 2012..The current status of these and other new developments in the treatment of cystic fibrosis are reviewed...- Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patientsMatthias Griese
Children s Hospital, University of Munich, Lindwurmstr 4, 80337 München, Germany
Respir Res 6:133. 2005..So far, longitudinal measurements of surfactant function in CF patients are lacking and it remains unclear how these alterations relate to the progression of airway inflammation as well as decline in pulmonary function over time... - Cystic fibrosis: pathogenesis and future treatment strategiesFelix A Ratjen
Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8
Respir Care 54:595-605. 2009..This review summarizes our current understanding of the pathophysiology and treatment of cystic fibrosis lung disease... - What's new in CF airway inflammation: an updateFelix Ratjen
Hospital for Sick Children, Toronto, Ontario, Canada
Paediatr Respir Rev 7:S70-2. 2006.... - Diagnosing and managing infection in CFFelix Ratjen
Hospital for Sick Children, Toronto, Ontario, Canada
Paediatr Respir Rev 7:S151-3. 2006..In addition, the optimal duration of therapy type of inhaled antibiotic as well as the optimal dose has not been clarified. Studies are currently ongoing to resolve these issues... - Pharmacokinetics of inhaled colistin in patients with cystic fibrosisF Ratjen
Children s Hospital, University of Duisburg Essen, Essen, Germany
J Antimicrob Chemother 57:306-11. 2006..Inhaled colistin is commonly used in patients with cystic fibrosis (CF), but only limited data are available to define its pharmacokinetic profile... - New pulmonary therapies for cystic fibrosisFelix Ratjen
Division of Respiratory Medicine, Hospital for Sick Children, Toronto, Canada
Curr Opin Pulm Med 13:541-6. 2007..This review addresses recent therapeutic strategies that either target the underlying defect or early steps in cystic fibrosis pathophysiology... - Recent advances in cystic fibrosisF Ratjen
Hospital for Sick Children, Toronto, Ontario, Canada
Paediatr Respir Rev 9:144-8. 2008..The review specifically focuses on those developments that have direct implications for patient care or those in which clinical trials suggest benefits that may impact on the treatment of CF patients in the near future... - Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosisFelix Ratjen
Division of Respiratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada
Curr Opin Pulm Med 12:428-32. 2006..aeruginosa infection. There are also studies showing that early treatment can eradicate the organism in the majority of cases... - Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trialFelix Ratjen
Division of Respiratory Medicine, Department of Pediatrics, University of Toronto, Hospital for Sick Children, 555 University Avenue, Toronto M5G 1X8, Ontario, Canada
Thorax 65:286-91. 2010.... - A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patientsWilfried H Nikolaizik
Department of Pediatrics, University Hospital Essen, Essen, Germany
Can Respir J 15:259-62. 2008..However, to date no comparative data are available for different dose regimens used in clinical practice... - Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosisPadmaja Subbarao
Division of Pediatric Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada
Pediatr Pulmonol 42:471-6. 2007..There was no difference in microbiologic yield between pre- and post-HS throat swabs. In this pilot study, inhalation of HS was well tolerated in CF infants. These results support a study of the efficacy of HS in this age group... - beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung diseaseRainer Buscher
Children s Hospital, University of Essen, Germany
Pharmacogenetics 12:347-53. 2002..These data provide the first evidence suggesting that polymorphisms of the beta2AR gene contribute to clinical severity and disease progression in cystic fibrosis... - The approach to Pseudomonas aeruginosa in cystic fibrosisGlenda N Bendiak
Department of Pediatrics, Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada
Semin Respir Crit Care Med 30:587-95. 2009..Nonantibiotic approaches to address P. aeruginosa infection are currently being developed and may expand the therapeutic repertoire in the future... - Cystic fibrosis: a review of pulmonary and nutritional therapiesReshma Amin
Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada
Adv Pediatr 55:99-121. 2008.... - Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung diseaseValerie Waters
Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada
Am J Respir Crit Care Med 183:635-40. 2011..maltophilia infection on CF lung disease is unknown... - MRI: the next frontier for cystic fibrosis clinicians?Reshma Amin
Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Avenue Toronto, ON M5G 1X8, Canada
Expert Rev Respir Med 2:179-82. 2008..MRI examinations were found to be comparable to CT scans and may, therefore, potentially be a useful imaging technology to evaluate lung disease in CF patients... - Beta2-agonists for asthma: the pediatric perspectivePadmaja Subbarao
Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Clin Rev Allergy Immunol 31:209-18. 2006..Finally, the potential detrimental effects of long- and short-acting beta-agonists in infants and children are discussed... - The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosisReshma Amin
Department of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada
Chest 137:171-6. 2010..Our aim was to determine the effect of persistent infection with A fumigatus on pulmonary exacerbations and lung function in children with CF... - Exhaled nitric oxide in children after accidental exposure to chlorine gasHartmut Grasemann
Children s Hospital, Department of Pediatrics, University of Duisburg Essen, Essen, Germany
Inhal Toxicol 19:895-8. 2007..No changes in exhaled nitric oxide were seen in asymptomatic children. These data suggest that acute chlorine gas exposure results in a mild increase of exhaled nitric oxide in symptomatic children... - Hypertonic saline improves the LCI in paediatric patients with CF with normal lung functionReshma Amin
Hospital for Sick Children, 555 University Avenue, Toronto Ontario M5G 1X8, Canada
Thorax 65:379-83. 2010..Clinical trial number NCT00635141... - Inhalation of Moli1901 in patients with cystic fibrosisHartmut Grasemann
The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada
Chest 131:1461-6. 2007..Moli1901 stimulates an alternative chloride channel and may thus compensate for the CFTR deficiency in the airway epithelium of CF patients... - Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a reviewFelix Ratjen
Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G1X8
J Cyst Fibros 8:361-9. 2009..An optimal treatment regimen for patients with CF with early or intermittent P. aeruginosa infections remains a high priority to maintain long-term lung health... - Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot projectAllan L Coates
Division of Nuclear Medicine, Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada
Pediatr Pulmonol 43:753-9. 2008..Patients with cystic fibrosis spend as much 30 min a day inhaling tobramycin. Could a new rapid system deposit the equivalent amount of tobramycin faster?.. - Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosisHartmut Grasemann
The Hospital for Sick Children, Division of Respiratory Medicine, 555 University Ave, Toronto, ON, M5G 1X8 Canada
Am J Respir Crit Care Med 174:208-12. 2006..Nitric oxide formation is deficient in airways of patients with cystic fibrosis (CF). Since nitric oxide has bronchodilatory effects, nitric oxide deficiency may contribute to airway obstruction in CF... - Increased arginase activity in cystic fibrosis airwaysHartmut Grasemann
Children s Hospital, University of Duisburg Essen, Essen, Germany
Am J Respir Crit Care Med 172:1523-8. 2005..Airway nitric oxide concentrations are reduced in cystic fibrosis (CF). Arginases compete for L-arginine, the substrate of nitric oxide synthesis... - Early interventions in CFFelix Ratjen
Department of Pediatrics, Children's Hospital, University of Essen, Germany
Pediatr Pulmonol Suppl 26:88-90. 2004 - Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosisMatthias Griese
Children s Hospital, University of Munich, Munich, Germany
Am J Respir Crit Care Med 170:1000-5. 2004.... - A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosisDirk Schnabel
Department of Pediatric Endocrinology and Diabetology, Children s Hospital, Charite, Berlin, Germany
Pediatrics 119:e1230-8. 2007..This trial was designed as a multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy and safety of 2 dosages of growth hormone in cystic fibrosis... - Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patientsWallace Lam
Department of Pharmacy Services, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
J Antimicrob Chemother 59:1135-40. 2007..In addition, we aimed to assess whether certain patient characteristics affect tobramycin pharmacokinetics and, therefore, dosing... - Cystic fibrosisFelix Ratjen
Department of Paediatrics, University of Essen, Essen, Germany
Lancet 361:681-9. 2003..Here, we summarise advances in understanding and treatment of cystic fibrosis, focusing on pulmonary disease, which accounts for most morbidity and deaths... - Multidrug-resistant organisms in cystic fibrosis: management and infection-control issuesValerie Waters
Division of Infectious Diseases, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8 Canada
Expert Rev Anti Infect Ther 4:807-19. 2006..Until more is known about their pathogenicity and effect on clinical outcomes, physicians should be aware of the potential transmissibility of these organisms and implement adequate infection control strategies... - Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosisDimas Mateos-Corral
Division of Respiratory Medicine, Hospital for Sick Children, Toronto, Canada
Pediatr Pulmonol 44:939-40. 2009..Histological analysis and in-vitro testing of the cast were important factors in choosing the adequate therapy in this patient... - Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxideHartmut Grasemann
Department of Pediatrics, University of Essen, Germany
Am J Respir Crit Care Med 167:1113-6. 2003..These data suggest that variants in the neuronal nitric oxide synthase gene contribute to the variability of airway nitric oxide concentrations in healthy females... - Endothelial nitric oxide synthase variants in cystic fibrosis lung diseaseHartmut Grasemann
Children s Hospital, University of Essen, Essen, Germany
Am J Respir Crit Care Med 167:390-4. 2003..aeruginosa... - Sputum induction in routine clinical care of children with cystic fibrosisSuhail Al-Saleh
Division of Respiratory Medicine, Toronto, Ontario, Canada Research Institute, The Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada
J Pediatr 157:1006-1011.e1. 2010..To determine the microbiological yield of induced sputum (IS) samples compared with conventional airway samples, spontaneously expectorated sputum and throat swabs, in children with cystic fibrosis (CF) attending an outpatient clinic... - Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasiaSuhail Al-Saleh
University of Toronto, Toronto, Ontario, Canada
Pediatrics 127:e1615-20. 2011..Early transcatheter embolization seems to be effective, but long-term outcomes still need to be assessed... - Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosisGreg D Wells
Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
Pediatr Pulmonol 43:345-53. 2008..The Habitual Activity Estimation Scale (HAES) questionnaire has been shown to be a feasible tool to measure physical activity however the reliability and validity have yet to be determined in the CF population... - P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influxRainer Buscher
Department of Pediatrics, University Children s Hospital, Hufelandstr 55, 45122 Essen, Germany
Pharmacogenet Genomics 16:199-205. 2006..We also assessed the impact of the genetic variants on Ca2+-influx of P2Y2-null cells transfected with several P2Y2 receptor haplotypes... - Assessment of body composition in pediatric patients with cystic fibrosisGreg D Wells
Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
Pediatr Pulmonol 43:1025-32. 2008..Maintaining nutritional sufficiency is challenging for CF patients and therefore accurate monitoring is important for their clinical management... - Dornase in non-CFFelix Ratjen
Department of Pediatrics, Children's Hospital, University of Essen, Germany
Pediatr Pulmonol Suppl 26:154-5. 2004 - Exercise and physical activity in children with cystic fibrosisDonna L Wilkes
Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8
Paediatr Respir Rev 10:105-9. 2009.... - Airway nitric oxide in Duchenne muscular dystrophyVolker Straub
Children's Hospital, University of Essen, Germany
J Pediatr 141:132-4. 2002..02) or 17 adult male control subjects (18.5 +/- 1.8 parts per billion, P <.001). These findings provide indirect evidence that NOS1 contributes significantly to fractional exhaled nitric oxide in healthy children... - Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosisMatthias Griese
Department of Pediatric Ludwig Maximilians University, Munich, Germany
Am J Respir Crit Care Med 169:822-8. 2004..Reversion of markers of oxidative injury may need longer treatment, higher doses, or different types of antioxidants... - Restoring airway surface liquid in cystic fibrosisFelix Ratjen
N Engl J Med 354:291-3. 2006 - Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patientsFelix Ratjen
Division of Respiratory Medicine Hospital for Sick Children, Canada
Pediatr Pulmonol 42:249-55. 2007..However, because variability between patients is considerable, treatment decisions should not be based on P. aeruginosa antibody levels alone... - Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapyBenjamin Gaston
Department of Pediatric Pulmonary Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
Am J Respir Crit Care Med 165:387-90. 2002..We speculate that normalization of airway nitrogen redox balance could contribute to the beneficial effects of antipseudomonal therapy on lung function in CF... - Reduced lung function in cystic fibrosis: a primary or secondary phenotype?Stephanie D Davis
Am J Respir Crit Care Med 178:2-3. 2008 - Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patientsSabine Ridder Schaphorn
Institute of Medical Microbiology, University of Muenster Hospital, Domagkstr 10, 48149 Muenster, Germany
J Clin Microbiol 45:2979-84. 2007..In CF patients, the oropharynx, and not the nose, was the predominant site of S. aureus infection and persistence. Hence, it is unlikely that CF patients will benefit from topical treatment strategies to eradicate nasal carriage... - Mucolytics in cystic fibrosisMarkus O Henke
Department of Pulmonary Medicine, Philipps University Marburg, 35043 Marburg, Germany
Paediatr Respir Rev 8:24-9. 2007..Ultimately, drugs that are mucokinetic, which preserve viscoelasticity, rather than mucolytic may prove to be beneficial for CF lung disease in the future... - Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosisJacques Brouard
Inserm E213, Armand Trousseau Hospital, Paris, and the Department of Pediatrics, Georges Clemenceau Hospital, Caen, France
J Infect Dis 191:1988-91. 2005..fumigatus. These results suggest that polymorphisms in the promoter region of the IL-10 gene may influence the host response to A. fumigatus in the context of CF... - Bronchoalveolar lavage protein patterns in children with malignancies, immunosuppression, fever and pulmonary infiltratesManfred Neumann
Kinderklinik and Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Ludwig-Maximilians-University, Munich, Germany
Proteomics 2:683-9. 2002..Future target regions of interest were identified. Sample prefractionation and the selection of suitable narrow isoelectric point ranges will be necessary for optimized detection and separating conditions... - Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosisChih-Min Tang
Department of Pharmacology, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636, USA
Pharmacogenet Genomics 15:321-7. 2005..None of the SNPs identified in A2B receptors are likely to be modifiers in CF... - Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosisKarl Paul
Department of Pediatric Pneumology and Immunology, Charit, Germany
Am J Respir Crit Care Med 169:719-25. 2004..We conclude that in patients with CF, an increase in neutrophilic airway inflammation is found that is positively influenced by rhDNase treatment... - Gender-specific disease modification by NOS3Hartmut Grasemann
Br J Haematol 126:160; author reply 161. 2004